These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 26473193)
21. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Davicioni E; Finckenstein FG; Shahbazian V; Buckley JD; Triche TJ; Anderson MJ Cancer Res; 2006 Jul; 66(14):6936-46. PubMed ID: 16849537 [TBL] [Abstract][Full Text] [Related]
22. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Parham DM; Qualman SJ; Teot L; Barr FG; Morotti R; Sorensen PH; Triche TJ; Meyer WH; Am J Surg Pathol; 2007 Jun; 31(6):895-901. PubMed ID: 17527077 [TBL] [Abstract][Full Text] [Related]
23. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors. de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386 [TBL] [Abstract][Full Text] [Related]
24. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440 [TBL] [Abstract][Full Text] [Related]
25. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621 [TBL] [Abstract][Full Text] [Related]
26. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382 [TBL] [Abstract][Full Text] [Related]
27. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH; Mercado GE; Laé M; Ladanyi M Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015 [TBL] [Abstract][Full Text] [Related]
28. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]
29. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887 [TBL] [Abstract][Full Text] [Related]